DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

What's the purpose of the trial?

This is a phase 1 study evaluating the safety, dosage and tolerability of belantamab mafodotin in participants with relapsed or refractory multiple myeloma with both normal and impaired liver function.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

Last Updated

3 months ago

Patient Screener

Participating Centers

There are 13 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Belantamab Mafodotin is an antibody-drug conjugate (ADC) that binds to BCMA on tumor cell surfaces. Belantamab Mafodotin is used in the treatment of multiple myeloma.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Patients with Normal Hepatic Function

Accepting patients

Patients with Moderate Hepatic Impairment

Accepting patients

Patients with Severe Hepatic Impairment

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.